CR11724A - Agente para tratar enfermedades - Google Patents

Agente para tratar enfermedades

Info

Publication number
CR11724A
CR11724A CR11724A CR11724A CR11724A CR 11724 A CR11724 A CR 11724A CR 11724 A CR11724 A CR 11724A CR 11724 A CR11724 A CR 11724A CR 11724 A CR11724 A CR 11724A
Authority
CR
Costa Rica
Prior art keywords
agent
treat diseases
composition
regulatory
administered
Prior art date
Application number
CR11724A
Other languages
English (en)
Inventor
Elmar Kraus
Christoph Bruecher
Benjamin Daelken
Matthias Germer
Frank Osterroth
Christoph Uherek
Silke Aigner
Daniele Wolf
Sybille Kaiser
Juergen Lindner
Andrea Wartenberg-Demand
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0804686A external-priority patent/GB0804686D0/en
Priority claimed from GB0817811A external-priority patent/GB0817811D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of CR11724A publication Critical patent/CR11724A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona una composición farmacéutica para tratar una enfermedad autoinmune, que comprende un portador farmacéutico aceptable y un agente capaz de activar células T regulatorias CD4+CD25+, en donde la composición se va a administrar a un sujeto en una dosis del agente 0.2 mg a 30 mg.
CR11724A 2008-03-13 2010-10-11 Agente para tratar enfermedades CR11724A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0804686A GB0804686D0 (en) 2008-03-13 2008-03-13 Humanized antibody
GB0817811A GB0817811D0 (en) 2008-09-29 2008-09-29 Agent for treating disease

Publications (1)

Publication Number Publication Date
CR11724A true CR11724A (es) 2011-06-07

Family

ID=40756949

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11724A CR11724A (es) 2008-03-13 2010-10-11 Agente para tratar enfermedades

Country Status (16)

Country Link
US (1) US9334325B2 (es)
EP (1) EP2265643B1 (es)
JP (1) JP5597553B2 (es)
KR (1) KR20100135257A (es)
CN (1) CN102027017A (es)
AU (1) AU2009231325B2 (es)
BR (1) BRPI0909048A2 (es)
CA (1) CA2718184A1 (es)
CO (1) CO6311007A2 (es)
CR (1) CR11724A (es)
IL (1) IL207891A0 (es)
MX (1) MX2010010028A (es)
RU (1) RU2539110C2 (es)
SG (1) SG190598A1 (es)
WO (1) WO2009121690A1 (es)
ZA (1) ZA201007215B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
WO2009124815A1 (en) * 2008-03-13 2009-10-15 Biotest Ag Agent for treating disease
RU2540018C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
MX2011003335A (es) * 2008-09-29 2011-04-27 Biotest Ag Composicion para tratar enfermedad.
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
AU2010292486B2 (en) 2009-08-27 2014-08-07 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
MX2013002488A (es) 2010-09-03 2013-06-03 Biomet Biologics Llc Métodos y composiciones para suministrar un antagonista del receptor interleucina-1.
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
EP3132802B1 (en) * 2014-02-21 2020-06-17 IDAC Theranostics, Inc. Therapeutic agent for solid cancer
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT90657B (pt) 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0462229A4 (en) 1989-05-02 1992-03-11 Genelabs Incorporated Chemically modified cd4 peptide fragments having anti-retroviral properties
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5871732A (en) 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0663836B1 (en) 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
JPH09510952A (ja) 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
US20020068057A1 (en) 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
EP1161955A3 (en) 1995-05-18 2001-12-19 Ortho Pharmaceutical Corporation Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
WO1998014211A1 (en) 1996-10-01 1998-04-09 Celltech Therapeutics Limited Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
DE19722888A1 (de) 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
DE05075555T1 (de) 1999-06-09 2007-02-08 Immunomedics, Inc. Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
WO2001093908A1 (en) 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
DE10050935A1 (de) 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
CN1492759A (zh) 2001-01-16 2004-04-28 Ѫ�������������ι�˾ 预防或治疗血液透析中血管通路和其它血管移植物故障的装置及方法
JP4295513B2 (ja) 2001-03-07 2009-07-15 チルドレンズ メディカル センター コーポレーション ミニ細胞ディスプレイを用いるペプチドディスプレイライブラリーをスクリーニングする方法
EP1241249A1 (en) 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
GB2376466A (en) 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
JP4448906B2 (ja) 2001-06-14 2010-04-14 イシス イノベーション リミテッド Ｃｄ４特異的抗体ｔｒｘ１およびその使用
PT1451224E (pt) 2001-12-04 2012-10-09 Theramab Llc Péptido ou proteína contendo um anel c¿- d da família de receptores cd28
DE10212108A1 (de) 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
MXPA05010778A (es) 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
EP1600164A3 (de) 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
JP2008503593A (ja) 2004-06-22 2008-02-07 トーラーレックス， インク． 霊長類で寛容を誘導するための抗ｃｄ４抗体で最適化された投薬
JPWO2006035876A1 (ja) 2004-09-29 2008-05-15 興和株式会社 関節リウマチの予防及び／又は治療薬
WO2006050949A2 (de) 2004-11-11 2006-05-18 Tegenero Ag Superagonistische anti-cd28 antikörper
WO2006055077A2 (en) 2004-11-12 2006-05-26 The University Of North Carolina At Charlotte Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
JP4730733B2 (ja) * 2005-05-02 2011-07-20 国立大学法人京都大学 ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
SG10201504917PA (en) * 2005-07-11 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
CA2619695A1 (en) 2005-08-18 2007-02-22 Genmab A/S Therapy with cd4 binding peptides and radiation
SG192479A1 (en) 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
CN103360496B (zh) 2006-01-05 2015-11-18 健泰科生物技术公司 抗ephb4抗体及其使用方法
EP2001510A4 (en) 2006-03-16 2010-06-09 Genentech Inc METHODS OF TREATING LUPUS USING CD4 ANTIBODIES
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
US20090208471A1 (en) 2006-04-07 2009-08-20 Yun Theodore J Isolation and Use of Human Regulatory T Cells
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
ES2825718T3 (es) 2007-02-01 2021-05-17 Univ Der Johannes Gutenberg Univ Mainz Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
EP3067368A1 (en) 2007-04-27 2016-09-14 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
WO2009124815A1 (en) 2008-03-13 2009-10-15 Biotest Ag Agent for treating disease
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
EP2101173A1 (en) 2008-03-14 2009-09-16 Vivalis In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
ES2335381B1 (es) 2008-09-24 2011-02-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
MX2011003335A (es) 2008-09-29 2011-04-27 Biotest Ag Composicion para tratar enfermedad.

Also Published As

Publication number Publication date
US20110059084A1 (en) 2011-03-10
EP2265643A1 (en) 2010-12-29
EP2265643B1 (en) 2016-10-19
RU2010141826A (ru) 2012-04-20
US9334325B2 (en) 2016-05-10
JP5597553B2 (ja) 2014-10-01
SG190598A1 (en) 2013-06-28
KR20100135257A (ko) 2010-12-24
ZA201007215B (en) 2016-08-31
MX2010010028A (es) 2011-08-17
AU2009231325A1 (en) 2009-10-08
CN102027017A (zh) 2011-04-20
WO2009121690A1 (en) 2009-10-08
JP2011516416A (ja) 2011-05-26
BRPI0909048A2 (pt) 2015-11-24
CA2718184A1 (en) 2009-10-08
AU2009231325B2 (en) 2014-09-18
CO6311007A2 (es) 2011-08-22
IL207891A0 (en) 2010-12-30
RU2539110C2 (ru) 2015-01-10

Similar Documents

Publication Publication Date Title
CR11724A (es) Agente para tratar enfermedades
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
CR11723A (es) Agente para tratar enfermedad
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
NZ604029A (en) Methods of treating bladder cancer
BR112012023021A2 (pt) compostos de indazol e seus usos
PH12016500619A1 (en) Dry powder inhaler
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
NZ707377A (en) Combination therapy methods for treating proliferative diseases
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
CO6771406A2 (es) Una composición combinada
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
SE0950392L (sv) Sammansättning för behandling av hudåkommor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)